Downward price pressure and selling activity affecting Ocugen stock are typically driven by the inherent volatility of clinical-stage biotechnology equities, quarterly reports detailing rising research and development expenses, and periodic cash burn concerns. Because pre-revenue biotech companies rely heavily on successful clinical trials and regulatory approvals, any dilution from capital-raising offerings, delays in trial timelines, or broader market rotations away from speculative healthcare stocks can trigger sharp pullbacks and multiple compression on public exchanges.